ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM
Abstract Number: 2396
A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2337
A Mediation Analysis of Tofacitinib’s Effects on SF-36: The Roles of Fatigue, Pain, Stiffness, and Mobility in Ankylosing Spondylitis
(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 1869
A miRNA signature consisting of high Let7i-5p, high miR-483-5p, low miR-223- 3p characterizes connective tissue diseases with interstitial lung disease
(1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II
10:30AM-12:30PM
Abstract Number: 2204
A Novel Framework for Teratogenicity Counseling for Adolescents and Young Adults (AYAs) with Rheumatic Disease on Teratogenic Medications
(2195–2226) Reproductive Issues in Rheumatic Disorders Posters
10:30AM-12:30PM
Abstract Number: 2155
A Novel TNFAIP3 Mutation Associated with Large Vessel Vasculitis: Expanding the Phenotypic Spectrum of A20 Haploinsufficiency
(2124–2158) Pediatric Rheumatology – Clinical Poster III
10:30AM-12:30PM
Abstract Number: 2011
A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV)
(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II
10:30AM-12:30PM
Abstract Number: 2012
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II
10:30AM-12:30PM
Abstract Number: 2181
A Pilot High-Fidelity Simulation for Pediatric Rheumatology Learners
(2159–2194) Professional Education Poster
10:30AM-12:30PM
Abstract Number: 2247
A Pilot Study to identify novel autoantibody biomarkers in Rheumatoid Arthritis (RA) patients using Immunome Protein Array
(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2371
A Predictive Model Combining Clinical and Laboratory Parameters to Predict anti-TNF Response in Patients with Psoriatic Arthritis
(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III
10:30AM-12:30PM
Abstract Number: 2053
A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III
10:30AM-12:30PM
Abstract Number: 1923
A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
(1914–1935) Health Services Research Poster III
10:30AM-12:30PM
Abstract Number: 2177
A Rheumatologic Ultrasound (RhUS) Educational Framework: Expert Consensus on RhUS Skills for Adult Rheumatology Fellows in the United States
(2159–2194) Professional Education Poster
10:30AM-12:30PM
Abstract Number: 2542
A Rule Based NLP Pipeline for Glucocorticoid exposure
(2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III
10:30AM-12:30PM
Abstract Number: 2494
Abatacept Reduces CD319+ (SLAM-F7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 62
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology